Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Significant Decrease in Short Interest

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the recipient of a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 55,796 shares, a decrease of 84.1% from the July 15th total of 350,806 shares. Based on an average daily trading volume, of 2,500 shares, the short-interest ratio is presently 22.3 days.

Hansa Biopharma AB (publ) Stock Performance

OTCMKTS:HNSBF remained flat at $3.70 during trading hours on Thursday. The stock’s 50 day moving average is $3.06 and its 200 day moving average is $2.96. Hansa Biopharma AB has a fifty-two week low of $2.90 and a fifty-two week high of $3.70.

Analysts Set New Price Targets

Separately, Danske began coverage on Hansa Biopharma AB (publ) in a research note on Tuesday, June 16th. They issued a “buy” rating for the company. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy”.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.